4503 Astellas Pharma
- 1510.0
- -26.0-1.69%
Astellas Pharma News
Astellas Pharma: U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY(avacincaptad pegol intravitreal solution) for Geograph
Astellas Pharma: IZERVAY (avacincaptad pegol) FDA accepts re-application for partial class 1 change approval
Astellas Pharma: Corporate Governance Report 2024/12/24
Astellas Pharma: Corporate Governance Report
Astellas Pharma: Corporate Governance Report 2024/12/24
Astellas Pharma: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Astellas Pharma: Astellas Provides Update on IZERVAY (avacincaptad pegol intravitreal solution) Supplemental New Drug Application
Astellas Pharma: The latest information on IZERVAY (avacincaptad pegol) partial change approval application in the US
Astellas Pharma: Confirmation letter
Astellas Pharma: Half Year Report - Term 20 (2024/04/01 - 2025/03/31)
Astellas Pharma: Notice Regarding Foreign Exchange Loss
Astellas Pharma: About recording foreign exchange losses
Astellas Pharma: Presentation Material for Information Meeting (Q2 YTD/FY2024)
Astellas Pharma: Supplementary Documents (Q2 YTD/FY2024)
Astellas Pharma: Financial Results (Q2 YTD/FY2024)
Astellas Pharma: Supplementary financial information for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025
Astellas Pharma: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025
Astellas Pharma: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [IFRS] (consolidated)
Astellas Pharma: Astellas Provides Update on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the European Union
Astellas Pharma: Update on avacincaptad pegol (ACP) European sales approval application
No Data